GlassScriptPhysician profile
James W Gorman
NPI 1750356002
$2,820.84
in general payments reported to CMS, 2019-2025
30 companies · $64.12 in 2025
The $64.12 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $353 · 2021: $977 · 2022: $591 · 2023: $271 · 2024: $313 · 2025: $64.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.58 | 2019-2023 | |
| Pfizer INC. | $209.84 | 2019-2024 | |
| Hologic Sales and Service, LLC | $175.74 | 2021-2024 | Myosure Tissue Removal Device, Novasure, Aptima |
| Gynesonics, INC. | $156.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.43 | 2019-2024 | |
| Baxter Healthcare | $124.84 | 2022 | |
| Organon LLC | $93.53 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $79.29 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $74.39 | 2021 | |
| Medtronic, INC. | $69.77 | 2021-2024 | Interstim |
| Astellas Pharma US INC | $69.03 | 2024-2025 | Veozah |
| Coloplast Corp | $60.40 | 2019-2020 | |
| Covidien LP | $53.61 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $47.57 | 2024-2025 | Myfembree |
| Myovant Sciences INC. | $46.63 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.75 | 2019 | |
| Therapeuticsmd, INC. | $37.74 | 2019-2022 | |
| Biogen, INC. | $35.92 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $32.15 | 2021-2024 | Slynd |
| Minerva Surgical, INC | $28.45 | 2024 | |
| Meditrina | $28.05 | 2022 | |
| Scynexis, INC. | $21.99 | 2022 | |
| Coopersurgical, INC. | $20.05 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Medline Industries LP | $15.73 | 2022 | |
| Convatec INC. | $14.29 | 2020 | |
| Boston Scientific Corporation | $13.75 | 2020 | |
| Novo Nordisk INC | $13.32 | 2020 | |
| Evofem Biosciences, INC. | $11.92 | 2021 | |
| Eisai INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.